IBEF Research: Ranbaxy Laboratories Limited

RELATED NEWS Ranbaxy signs licensing agreement with Debiopharm Ranbaxy Q3 pat up 651% at Rs 1404 mn Not eyeing any acquisition in France: Ranbaxy Ranbaxy's revenue growth to be led by Terapia acquisition RLL receives approval to commercialize Furosemide tablets ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 28/05/12 Are Mutual Funds betting on Ranbaxy Labs?

The Company has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe with a presence in 23 of the Top 25 pharma markets of the world. Ranbaxy has robust operations USA, UK, France, Germany, Russia, India, Brazil, China and South Africa and is strengthening its business in Japan, Italy, Spain and several other markets in Asia Pacific and Latin America. In India a strong market presence and a significant distribution network give the company an edge over its competition. A balanced geographical presence coupled with a strong product flow from a wide therapeutic range serve as the business building blocks of the Company.

The Company's vision is to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets. It also aspires to be amongst the Top 5 generic players with US $5 Bn in sales, by 2012.Together with the commitment of a 10,000 strong multicultural workforce, Ranbaxy continues to aggressively pursue its mission to become a Research-based International Pharmaceutical Company.

Ranbaxy Financials

Ranbaxy has witnessed a CAGR of 16% in revenues since 2002.This growth has been led by its foray in the international generics markets, primarily the USA. Its other key geographies i.e. Europe and BRICS Countries have been the other key contributors to growth over the past three years. In 2005, however the revenues and profits were under pressure on account of fewer new launches and pricing pressures in the US, the Company's key market.

The Company is targeting higher growth in the future by focusing on gaining scale and size in USA, strengthening its position in Europe, through new launches and acquisitions. The Company has posted good H1-2006 results with sales of US$ 604Mn, Profit before tax and extraordinary items at US$ 54 Mn and Profit after Tax and minority interest at US$ 43 Mn. Post its strong H1 2006 results, the management has re-iterated its guidance of achieving 18% growth in sales in 2006.

Taken with permission from India Brand Equity Foundation